TOXICITY AND HAZARD OF ZOLMITRIPTAN (EXPERIMENTAL STUDY)

封面

如何引用文章

全文:

详细

Zolmitriptan is a widely used antimigraine drug, belongs to the group of second-generation tryptans, has a pronounced central mechanism of action and high selectivity to serotonin receptors of 5HT1D- and 5HT1B-types. Zolmitriptan belongs to hazard class 3 according to GOST 12.1.007-76: DL50 are 660 (495 - 881) mg/kg for male mice and 1045 (749 - 1292) mg/kg for female mice when administered into the stomach. When injected into the abdominal cavity, DL50 is 172 (131 - 225) mg/kg for male mice. The drug has a weak irritating effect on the mucous membranes of the eyes, does not irritate the skin, there are no signs of skin-resorptive action, and has a low ability to accumulate. The threshold of acute inhalation action is set at 0,9 mg/m3 for the effect on the functional state of the nervous system and liver. For the zolmitriptan aerosol, it is recommended to approve the tentative safe exposure level in the air of the working area at 0,01 mg/m3 and the tentative safe exposure level in the atmospheric air of urban and rural settlements at 0,0001 mg/m3.

作者简介

M. Bidevkina

Scientific Research Disinfectology Institute of Rospotrebnadzor

编辑信件的主要联系方式.
Email: bidevkinamv@niid.ru

Bidevkina Marina Vasil’evna

117246, Moscow

俄罗斯联邦

M. Golubeva

Joint-Stock Company «All-Union Scientific Center for the Safety of Biologically Active Compounds»

Email: golubevamargo@mail.ru

Golubeva Margarita Ivanovna

142450, Staraya Kupavna, Moscow region

俄罗斯联邦

I. Bobrineva

Joint-Stock Company «All-Union Scientific Center for the Safety of Biologically Active Compounds»

Email: ural955@mail.ru

Bobrineva Irina Alekseevna

142450, Staraya Kupavna, Moscow region

俄罗斯联邦

A. Limantsev

Scientific Research Disinfectology Institute of Rospotrebnadzor

Email: av.lim@yandex.ru

Limantsev Anatoliy Vladimirovich

117246, Moscow

俄罗斯联邦

T. Potapova

Scientific Research Disinfectology Institute of Rospotrebnadzor

Email: potapovatn@niid.ru

Potapova Tat›yana Nikolaevna

117246, Moscow

俄罗斯联邦

I. Razumnaya

Joint-Stock Company «All-Union Scientific Center for the Safety of Biologically Active Compounds»

Email: irina.r.3@mail.ru

Razumnaya Irina Nikolaevna

142450, Staraya Kupavna, Moscow region

俄罗斯联邦

A. Savchenko

Scientific Center for Biomedical Technology of the Federal Medical Biological Agency of the Russian Federation

Email: alursav@mail.ru

Savchenko Аlla Yur’evna

143442, Svetlye Gory Village, Krasnogorsk District, Moscow region

俄罗斯联邦

G. Ramenskaya

I.M. Sechenov First Moscow State Medical University

Email: ramenskaia@mail.ru

Ramenskaya Galina Vladislavovna

119991, Moscow

俄罗斯联邦

参考

  1. Kalashnikova L.A. Zomig – a new selective serotonin receptor agonist in the treatment of migraine attacks. Neurological journal; 1999; 4 (4): 37-40 (in Russian).
  2. Evolution of views on the causes of migraines. International neurological journal; 2009; 5(27). Available at: http://www.mif-ua.com/archive/article_print/11306 (accessed 02 August, 2019) (in Russian).

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bidevkina M.V., Golubeva M.I., Bobrineva I.A., Limantsev A.V., Potapova T.N., Razumnaya I.N., Savchenko A.Y., Ramenskaya G.V., 2020


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 81728 от 11 декабря 2013.